McIlrath & Eck LLC Has $469,000 Stake in Johnson & Johnson (NYSE:JNJ)

McIlrath & Eck LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 10.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,892 shares of the company’s stock after purchasing an additional 279 shares during the quarter. McIlrath & Eck LLC’s holdings in Johnson & Johnson were worth $469,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. ORG Partners LLC boosted its position in Johnson & Johnson by 1,202.2% in the 2nd quarter. ORG Partners LLC now owns 6,589 shares of the company’s stock valued at $967,000 after buying an additional 6,083 shares during the last quarter. Envestnet Portfolio Solutions Inc. lifted its stake in shares of Johnson & Johnson by 3.3% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 129,810 shares of the company’s stock valued at $18,973,000 after acquiring an additional 4,116 shares during the period. Cornerstone Wealth Management LLC boosted its holdings in Johnson & Johnson by 5.8% in the second quarter. Cornerstone Wealth Management LLC now owns 44,565 shares of the company’s stock valued at $6,514,000 after acquiring an additional 2,456 shares during the last quarter. Keudell Morrison Wealth Management increased its position in Johnson & Johnson by 3.4% in the second quarter. Keudell Morrison Wealth Management now owns 8,310 shares of the company’s stock worth $1,215,000 after purchasing an additional 272 shares during the period. Finally, Country Club Bank lifted its position in Johnson & Johnson by 24.7% during the 2nd quarter. Country Club Bank now owns 121,466 shares of the company’s stock valued at $17,710,000 after purchasing an additional 24,052 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Down 0.2 %

Johnson & Johnson stock opened at $149.26 on Wednesday. The company has a 50 day moving average of $157.84 and a 200-day moving average of $156.40. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The stock has a market capitalization of $359.35 billion, a PE ratio of 21.60, a price-to-earnings-growth ratio of 2.66 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.66 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th were given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.32%. The ex-dividend date of this dividend was Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 71.78%.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of recent research reports. Citigroup boosted their price target on shares of Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. Wolfe Research initiated coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Royal Bank of Canada increased their price target on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Bank of America reiterated a “neutral” rating and issued a $166.00 price objective on shares of Johnson & Johnson in a report on Tuesday. Finally, Guggenheim raised their target price on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Seven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $175.40.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.